Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1975 4
1976 36
1977 26
1978 69
1979 131
1980 87
1981 88
1982 112
1983 124
1984 84
1985 89
1986 78
1987 102
1988 106
1989 104
1990 91
1991 87
1992 62
1993 65
1994 44
1995 35
1996 25
1997 20
1998 28
1999 31
2000 35
2001 26
2002 26
2003 21
2004 31
2005 26
2006 36
2007 31
2008 48
2009 44
2010 42
2011 52
2012 53
2013 46
2014 54
2015 60
2016 57
2017 58
2018 50
2019 60
2020 67
2021 56
2022 66
2023 70
2024 24

Text availability

Article attribute

Article type

Publication date

Search Results

2,742 results

Results by year

Filters applied: . Clear all
Page 1
Showing results for labetalol
Your search for alfabetalol retrieved no results
Labetalol: a review of its pharmacology, pharmacokinetics, clinical uses and adverse effects.
MacCarthy EP, Bloomfield SS. MacCarthy EP, et al. Pharmacotherapy. 1983 Jul-Aug;3(4):193-219. doi: 10.1002/j.1875-9114.1983.tb03252.x. Pharmacotherapy. 1983. PMID: 6310529 Review.
Labetalol is a combined alpha- and beta-adrenoceptor blocking agent for oral and intravenous use in the treatment of hypertension. ...Labetalol administered alone or with a diuretic is often effective when other antihypertensive regimens have failed. ...
Labetalol is a combined alpha- and beta-adrenoceptor blocking agent for oral and intravenous use in the treatment of hypertension. .. …
Labetalol.
Carter BL. Carter BL. Drug Intell Clin Pharm. 1983 Oct;17(10):704-12. Drug Intell Clin Pharm. 1983. PMID: 6354658 Review.
Labetalol is a competitive antagonist of alpha 1-, beta 1-, and beta 2-adrenergic receptors. ...Reductions in heart rate are less pronounced with labetalol as compared with propranolol. Labetalol produces rapid reductions in blood pressure when administered i …
Labetalol is a competitive antagonist of alpha 1-, beta 1-, and beta 2-adrenergic receptors. ...Reductions in heart rate are less pro …
Distinct outcomes of labetalol exposed infants: case reports and systematic review.
Yang X, Hui L, Long H, Zou L. Yang X, et al. J Matern Fetal Neonatal Med. 2021 Jun;34(12):2012-2018. doi: 10.1080/14767058.2019.1651270. Epub 2019 Sep 11. J Matern Fetal Neonatal Med. 2021. PMID: 31510808 Review.
A systematic literature review was carried out followed by a retrospective analysis on neonatal labetalol withdrawal effects. RESULTS: It was discovered that labetalol withdrawal effects initially cause various degrees of hypotension, hypoglycemia, and bradycardia a …
A systematic literature review was carried out followed by a retrospective analysis on neonatal labetalol withdrawal effects. RESULTS …
Labetalol in hypertension.
[No authors listed] [No authors listed] Lancet. 1977 Apr 23;1(8017):890-1. Lancet. 1977. PMID: 67294 No abstract available.
Clinical pharmacology of labetalol.
Richards DA, Prichard BN. Richards DA, et al. Br J Clin Pharmacol. 1979;8(Suppl 2):89S-93S. Br J Clin Pharmacol. 1979. PMID: 43165 Free PMC article. Review.
1 The clinical pharmacology of labetalol has been evaluated using pharmacological and physiological test methods. 2 Labetalol displaces the log dose-response curves to the right of isoprenaline-induced increases in heart rate, cardiac output and decreases in diastol …
1 The clinical pharmacology of labetalol has been evaluated using pharmacological and physiological test methods. 2 Labetalol …
Labetalol: a review of its pharmacology and therapeutic use in hypertension.
Brogden RN, Heel RC, Speight TM, Avery GS. Brogden RN, et al. Drugs. 1978 Apr;15(4):251-70. doi: 10.2165/00003495-197815040-00002. Drugs. 1978. PMID: 25757 Review.
Labetalol is an orally active adrenoceptor blocking drug which is a competitive antagonist at both alpha- and beta-adrenoceptor sites. ...Unlike with conventional beta-adrenoceptor blocking drugs, acute administration of labetalol reduces peripheral vascular resista …
Labetalol is an orally active adrenoceptor blocking drug which is a competitive antagonist at both alpha- and beta-adrenoceptor sites …
Labetalol and other agents that block both alpha- and beta-adrenergic receptors.
Pearce CJ, Wallin JD. Pearce CJ, et al. Cleve Clin J Med. 1994 Jan-Feb;61(1):59-69; quiz 80-2. doi: 10.3949/ccjm.61.1.59. Cleve Clin J Med. 1994. PMID: 8124849 Free article. Review.
BACKGROUND: Labetalol, a compound that blocks both alpha- and beta-adrenergic receptors, is the only drug of its class currently available in the United States. OBJECTIVE: To review the pharmacology of labetalol and related compounds. SUMMARY: Unlike "pure" beta blo …
BACKGROUND: Labetalol, a compound that blocks both alpha- and beta-adrenergic receptors, is the only drug of its class currently avai …
Labetalol. A reappraisal of its pharmacology, pharmacokinetics and therapeutic use in hypertension and ischaemic heart disease.
Goa KL, Benfield P, Sorkin EM. Goa KL, et al. Drugs. 1989 May;37(5):583-627. doi: 10.2165/00003495-198937050-00002. Drugs. 1989. PMID: 2663413 Review.
Since labetalol was first reviewed in the Journal (1978), its scope of therapeutic use has expanded and become better defined. Labetalol is an adrenoceptor blocking drug with combined alpha- and beta-blocking properties. ...
Since labetalol was first reviewed in the Journal (1978), its scope of therapeutic use has expanded and become better defined. Lab …
Treatment of hypertension in the elderly with labetalol.
Sirgo MA, Boyd BK, Applegate WB. Sirgo MA, et al. Pharmacotherapy. 1989;9(5):295-302. doi: 10.1002/j.1875-9114.1989.tb04141.x. Pharmacotherapy. 1989. PMID: 2682551 Review.
To establish an individualized or patient-specific approach to their treatment, antihypertensive agents must be evaluated specifically in this subpopulation. Labetalol, an alpha- and beta-blocking agent, has been shown to lower blood pressure in young and elderly hypertens …
To establish an individualized or patient-specific approach to their treatment, antihypertensive agents must be evaluated specifically in th …
Labetalol. Current research and therapeutic status.
Wallin JD, O'Neill WM Jr. Wallin JD, et al. Arch Intern Med. 1983 Mar;143(3):485-90. doi: 10.1001/archinte.143.3.485. Arch Intern Med. 1983. PMID: 6338850 Review.
Labetalol hydrochloride is the prototype drug of a new class of antihypertensive agents that competitively and peripherally blocks both beta- and alpha-adrenergic receptors. ...
Labetalol hydrochloride is the prototype drug of a new class of antihypertensive agents that competitively and peripherally blocks bo …
2,742 results